Wedbush Initiates Coverage on Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA)

Equities research analysts at Wedbush started coverage on shares of Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) in a research report issued on Thursday, MarketBeat.com reports. The firm set an “outperform” rating and a $35.00 price target on the stock. Wedbush’s price objective indicates a potential upside of 38.83% from the company’s previous close.

A number of other equities analysts have also recently weighed in on DMRA. UBS Group assumed coverage on Damora Therapeutics, Inc. Common Stock in a report on Tuesday, February 17th. They set a “buy” rating and a $45.00 price objective on the stock. Guggenheim reissued a “buy” rating and set a $40.00 price objective (up from $36.00) on shares of Damora Therapeutics, Inc. Common Stock in a report on Tuesday, February 17th. Royal Bank Of Canada assumed coverage on Damora Therapeutics, Inc. Common Stock in a report on Friday, April 24th. They set an “outperform” rating and a $40.00 price objective on the stock. Lifesci Capital raised Damora Therapeutics, Inc. Common Stock to a “strong-buy” rating in a report on Monday, February 2nd. Finally, Evercore assumed coverage on Damora Therapeutics, Inc. Common Stock in a report on Wednesday, March 25th. They set an “outperform” rating and a $46.00 price objective on the stock. Two analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Damora Therapeutics, Inc. Common Stock currently has an average rating of “Moderate Buy” and a consensus price target of $42.00.

Damora Therapeutics, Inc. Common Stock Stock Performance

Shares of DMRA opened at $25.21 on Thursday. The stock’s 50-day simple moving average is $25.01 and its 200 day simple moving average is $25.20. The stock has a market capitalization of $1.55 billion, a price-to-earnings ratio of -4.52 and a beta of 1.50. Damora Therapeutics, Inc. Common Stock has a 52-week low of $2.45 and a 52-week high of $38.33.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) last issued its quarterly earnings data on Tuesday, May 12th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.23). On average, research analysts forecast that Damora Therapeutics, Inc. Common Stock will post -0.95 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Damora Therapeutics, Inc. Common Stock

Hedge funds have recently made changes to their positions in the company. Two Sigma Investments LP bought a new stake in Damora Therapeutics, Inc. Common Stock in the third quarter worth $76,000. Virtu Financial LLC bought a new stake in Damora Therapeutics, Inc. Common Stock in the third quarter worth $49,000. Connective Capital Management LLC bought a new stake in Damora Therapeutics, Inc. Common Stock in the third quarter worth $100,000. Sigma Planning Corp bought a new stake in Damora Therapeutics, Inc. Common Stock in the fourth quarter worth $334,000. Finally, Geode Capital Management LLC bought a new stake in Damora Therapeutics, Inc. Common Stock in the fourth quarter worth $266,000. 14.20% of the stock is currently owned by institutional investors.

Damora Therapeutics, Inc. Common Stock Company Profile

Galecto Inc is a clinical?stage biotechnology company developing small?molecule therapies that target key pathways involved in fibrotic and malignant diseases. The company’s research focuses on inhibiting galectin?3, an extracellular carbohydrate?binding protein implicated in inflammation, fibrosis and tumor progression, as well as lysyl oxidase?like 2 (LOXL2), an enzyme that crosslinks collagen and elastin in fibrotic tissue.

Its lead programs include GB0139, an inhaled galectin?3 inhibitor in Phase II trials for idiopathic pulmonary fibrosis and other fibrosing lung diseases, and GB1211, an oral galectin?3 inhibitor being evaluated for systemic fibrotic disorders.